Bentonville, ARNCT07467993Now EnrollingIRB Ready

Schizophrenia Clinical Trial in Bentonville, AR

Access cutting-edge schizophrenia treatment through this clinical trial at a research site in Bentonville. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Bentonville location

Preparing your pre-screening questions…

Expert Care in Bentonville

Access schizophrenia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related schizophrenia treatment provided free

Apply for This Bentonville Location

Check if you qualify for this schizophrenia clinical trial in Bentonville, AR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Bentonville

    Convenient for AR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Bentonville site if eligible
  4. 4Begin participation

About This Schizophrenia Study in Bentonville

The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Participant is aged 18 to 65 years, inclusive, at screening
Participant is capable of providing informed consent
Participant has a primary diagnosis of schizophrenia, established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Association 2013) criteria and confirmed by Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT)
Participant is willing and able to be confined to an inpatient setting for the study duration (except for the follow-up period), follow instructions, and comply with the protocol requirements
Participant is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening
The participant requires hospitalization for this acute exacerbation or relapse of symptoms
If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening
Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening a. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items: i. Item 1 (P1; delusions) ii. Item 2 (P2; conceptual disorganization) iii. Item 3 (P3; hallucinatory behavior) iv. Item 6 (P6; suspiciousness/persecution)

Exclusion Criteria

Any primary DSM-5 disorder other than schizophrenia within 12 months before screening (confirmed using Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) at screening)
History of treatment resistance to antipsychotic medications defined as inadequate response to two adequate courses of pharmacotherapy or previous clozapine treatment for treatment-resistant schizophrenia
Participants who need to be treated with drugs that are known to be moderate and strong CYP3A4 inhibitors and inducers will be excluded
Participants taking a long-acting injectable antipsychotic could not have received a dose of medication in the last 12 weeks (24 weeks for INVEGA TRINZA®) before baseline Other protocol-defined inclusion/exclusion criteria may apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bentonville?

Yes, this clinical trial (NCT07467993) has an active research site in Bentonville, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Schizophrenia Treatment Options in Bentonville, AR

If you're searching for schizophrenia treatment options in Bentonville, AR, this clinical trial (NCT07467993) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bentonville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced schizophrenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all schizophrenia clinical trials near you to find additional studies recruiting in your area.

More Schizophrenia Trials in Bentonville, AR

See all schizophrenia clinical trials recruiting in Bentonville — not just this study.

Browse Schizophrenia Trials in Bentonville →

Browse More Trials by Condition

Schizophrenia TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Bentonville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Bentonville, AR